BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ragozin E, Hesin A, Bazylevich A, Tuchinsky H, Bovina A, Shekhter Zahavi T, Oron-herman M, Kostenich G, Firer M, Rubinek T, Wolf I, Luboshits G, Sherman M, Gellerman G. New somatostatin-drug conjugates for effective targeting pancreatic cancer. Bioorganic & Medicinal Chemistry 2018;26:3825-36. [DOI: 10.1016/j.bmc.2018.06.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Furman O, Zaporozhets A, Tobi D, Bazylevich A, Firer MA, Patsenker L, Gellerman G, Lubin BCR. Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery. Pharmaceutics 2022;14:1505. [DOI: 10.3390/pharmaceutics14071505] [Reference Citation Analysis]
2 Tong S, Darwish S, Ariani HHN, Lozada KA, Salehi D, Cinelli MA, Silverman RB, Kaur K, Yang S. A Small Peptide Increases Drug Delivery in Human Melanoma Cells. Pharmaceutics 2022;14:1036. [DOI: 10.3390/pharmaceutics14051036] [Reference Citation Analysis]
3 Hashemzadeh A, Drummen GPC, Avan A, Darroudi M, Khazaei M, Khajavian R, Rangrazi A, Mirzaei M. When metal-organic framework mediated smart drug delivery meets gastrointestinal cancers. J Mater Chem B 2021;9:3967-82. [PMID: 33908592 DOI: 10.1039/d1tb00155h] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
4 Garcia-Sampedro A, Gaggia G, Ney A, Mahamed I, Acedo P. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies. J Clin Med 2021;10:566. [PMID: 33546207 DOI: 10.3390/jcm10040566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
5 Huang X, Ding L, Liu X, Tong R, Ding J, Qian Z, Cai L, Zhang P, Li D. Regulation of tumor microenvironment for pancreatic cancer therapy. Biomaterials 2021;270:120680. [PMID: 33588140 DOI: 10.1016/j.biomaterials.2021.120680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
6 Zhang C, Qu Y, Ma X, Li M, Li S, Li Y, Wu L. NQO1-selective activated prodrugs of combretastatin A-4: Synthesis and biological evaluation. Bioorganic Chemistry 2020;103:104200. [DOI: 10.1016/j.bioorg.2020.104200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
7 Worm DJ, Els‐heindl S, Beck‐sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Peptide Science 2020;112. [DOI: 10.1002/pep2.24171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
8 Sriram K, Salmerón C, Wiley SZ, Insel PA. GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets. Br J Pharmacol 2020;177:2434-55. [PMID: 32060895 DOI: 10.1111/bph.15028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
9 Chen W, Ding R, Tang J, Li H, Chen C, Zhang Y, Zhang Q, Zhu X. Knocking Out SST Gene of BGC823 Gastric Cancer Cell by CRISPR/Cas9 Enhances Migration, Invasion and Expression of SEMA5A and KLF2. Cancer Manag Res 2020;12:1313-21. [PMID: 32110105 DOI: 10.2147/CMAR.S236374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Patsenker L, Gellerman G. Fluorescent Reporters for Drug Delivery Monitoring. Isr J Chem 2020;60:504-18. [DOI: 10.1002/ijch.201900137] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
11 Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res 2019;148:104398. [PMID: 31415916 DOI: 10.1016/j.phrs.2019.104398] [Cited by in Crossref: 46] [Cited by in F6Publishing: 89] [Article Influence: 15.3] [Reference Citation Analysis]
12 White BH, Whalen K, Kriksciukaite K, Alargova R, Au Yeung T, Bazinet P, Brockman A, DuPont M, Oller H, Lemelin CA, Lim Soo P, Moreau B, Perino S, Quinn JM, Sharma G, Shinde R, Sweryda-Krawiec B, Wooster R, Bilodeau MT. Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo. J Med Chem 2019;62:2708-19. [PMID: 30735385 DOI: 10.1021/acs.jmedchem.8b02036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]